2023 Value Assessment Framework

September 28, 2023



© 2023 Institute for Clinical and Economic Review

ICER Speakers



Foluso Agboola, MBBS, MPH Vice President of Research



Sarah K. Emond, MPP President-Elect



Catherine Koola, MPH Director, Patient Engagement




Steven D. Pearson, MD, MSc President



Agenda for Today





Purpose of the ICER Value Assessment Framework

Transparency on measuring value

Describing how "value" is conceived of and evaluated in ICER reports

Encompass and reflect the experiences and values of patients

Incorporation of patient experiences and values

"Population-Level" Focus Explaining the "population level" perspective, as opposed to trying to serve as a shared decision-making tool to be used by individual patients and their clinicians

Experience following the 2020 VAF update:



35 ICER assessments



56 ICER publications since 2020



85 new drugs reviewed



17,000 Final Evidence Report downloads



Engaged with over 100 patient groups, patient reps, and caregivers



6,000 Report-at-a-Glance downloads

The 2023 VAF will focus on:

Patient Engagement

- Accessibility and inclusivity
- Share Your Story
- ICER Patient Council

HTA Methods Related to Health Equity

- Analyses of clinical trial diversity and racial/ethnic subpopulations
- Quantitative measures to guide discussion and voting on unmet need

Cost-effectiveness

- "Non-zero" inputs for societal perspective
- Dynamic pricing scenario
- Future methods development on value domains





HTA Methods Related to Health Equity



Cost-effectiveness



Patient Engagement

- Share Your Story form
- Small-group patient and caregiver discussions
- Patient compensation
- Accessibility and inclusivity of public meetings
- ICER Patient Council
- Enhanced patient-friendly materials

Share Your Story Form

		•
Please note that any inform with your name or any iden	ation you share below will not be associated ifiable information.	
individual input. Patient adv	: 10 minutes to complete and is intended for ocacy organizations should contact ICER's to learn how they can participate in this	Ŧ
Name*		
Email*		
Are you filling out this fo	rm as a patient or caregiver?*	
Are you filling out this fo	rm as a patient or caregiver?*	


What ICER Wants to Know

- Impact of condition on daily life
- Experience with previous/current treatments
- Experience with accessing/affording care
- Hopes for a new treatment
- Impact on caregivers/family




Small-Group Patient and Caregiver Discussions

- Increase diversity of patient participation during the scoping phase
- 90-minute call with ~5 patient/caregiver participants
- Insights from this call are summarized in our Patient Perspectives chapter




Fair Compensation for Patient Participation

- Formalize honoraria for select activities:
 - Small-group patient and caregiver discussions = \$100
 - Review of draft evidence report = \$500
 - Panelists at public meeting = \$500



Accessibility of Public Meeting

- Virtual attendance and remote testimony
- Closed captioning for all meetings
- If we return to in-person meetings:
 - Still offer hybrid meeting format
 - Travel grants



ICER Patient Council

- Publicly announced in July 2023
- 3 main objectives:
 - 1. Identify opportunities to improve patient engagement process
 - 2. Ensure diversity of patient participation
 - 3. Ensure accessibility and inclusivity of materials
- Council structure and meeting format

Patient-Friendly Resources

How to Share Your Lived Experience with ICER

What is the Scoping Phase?

The scoping phase is the first two months of ICER's research process. During this time, the ICER team is trying to "scope" or figure out what is most important to include in our report about the treatment and patient population we are researching. We do this by speaking to different members of the patient community to better understand the diversity of patient lived experience.



What Happens During this Phase?

V ICER notifies the patient community about the review V ICER offers introductory calls to meet with patient groups VICER offers scoping calls to figure out our research plan VICER publicly announces the review & publishes the Draft Scope VICER asks for public comments on the Draft Scope V ICER publishes the Revised Scope

© 2023 Institute for Clinical and Economic Review (ICER)

How to Respond to ICER's Work

Why Does ICER Request Your Input?

Health technology assessment (HTA) is a type of research process that involves all key participants in the health care system. In order for ICER to understand how well a new drug works and how much it could cost, we want to involve the people that this new drug may impact. That's why we invite patients, clinicians, health insurers, and drug makers to provide their perspectives on the new drug.



e and what matter



Sickle Cell Disease 2023

Population

This analysis included

adolescents and adults

not eligible to get a stem

ICER

cell transplant.

How Did ICER Calculate a Fair Price?

Using economic modeling, we calculated the cost effectiveness of lovo-cel and exacel based on how well they reduced acute and chronic complications, compared to standard of care. See below for what types with severe SCD who were of information ICER considered to calculate a fair price range for the two gene therapies.

Factors Included in ICER's Economic Analysis



Summary of ICER's Health Equity White Paper

Why Should We Support Health Equity in **Health Technology Assessment?**

Health technology assessment (HTA) is one way of creating a health system that is fair to everyone. Therefore, it is important to make sure that the process and methods of HTA follow best practices for achieving the goal of health equity.








Health equity is the idea that all people should have an equal opportunity to better health without any barriers related to race, ethnicity, gender identity, preferred language, where they live, or other important factors.

Objective of White Paper

To give recommendations for HTA that will help societies improve health equity for racial, ethnic, and socially disadvantaged groups.

@ 2023 Institute for Clinical and Economic Review (ICER)

ICER



ICERI



Patient Engagement

HTA Methods Related to Health Equity



2

Cost-effectiveness analysis



HTA Methods Related to Health Equity


• Clinical trial diversity

2

- Subpopulation analysis
- Patient input on clinical trial design
- Quantitative measures to guide discussion and voting on unmet need

Clinical Trial Diversity

- To promote conversations around equity in clinical trials of new drugs
- ICER-developed rating tool to evaluate Race/Ethnicity, Sex, and Age
 - Benchmark: Prevalence of the disease condition
 - Rating Categories: 'Good', 'Fair', 'Poor'
 - Multinational Trials: Rate US subpopulation




Subpopulation Analysis

- Race, sex, and age will be considered as presumptive subpopulations
- Targeted literature review and consultation with patients, clinical experts, and manufacturers to determine relevant subpopulations
- A formal credibility assessment tool to evaluate and present information on the credibility of subgroup findings




Patient Input on Clinical Trial Design

- To highlight industry-leading practices in incorporating patient perspective into their drug development programs
- Manufacturers are encouraged to describe methods used to collect patient experience and how they identified the outcomes most important to patients



HTA Methods Related to Health Equity

 Enhancing methods to capture and integrate "benefits beyond health" and "special ethical priorities"




2

Benefits Beyond Health and Special Ethical Priorities

- Change terminology away from "contextual considerations"
- Acknowledge and incorporate broader elements related to value that may or may not be quantifiable
- Improve capture of impact on health equity
- Improve consistency and transparency of deliberation and voting

Benefits Beyond Health and Special Ethical Priorities

- Move to 1-5 Likert scale voting of agreement with statements regarding the following elements that are important in making judgments regarding the value for money of new health care interventions:
 - Unmet need with current best treatments (informed by health shortfall)
 - Relevance of the condition for disadvantaged communities (informed by HIDI)
 - Impact on caregivers' lives
 - Mechanisms of action or of delivery that could improve access





Incorporating the patient voice



3

HTA Methods Related to Health Equity

Cost-effectiveness





- "Non-zero" inputs for impact of treatment on productivity
- "Dynamic price" scenario
- Process to evaluate potential application of the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) framework



"Non-zero" inputs for impact of treatment on productivity

- Capturing additional dimensions of impact of treatment from the "societal" perspective often challenged by lack of data
- Most accepted component of societal perspective is productivity, although ethical concerns remain important
- ICER will adopt a relatively new academic approach to crosswalk productivity gains for patients and caregivers from quality of life gains resulting from treatment

"Dynamic price" scenario

- Longstanding debate over whether CEA should try to estimate price increases and/or decreases over the lifespan of a new treatment
- Current adoption of dynamic pricing very limited
- Adoption of IRA has increased consideration of relevance of price decreases due to generic competition and/or negotiation
- Methodological and conceptual challenges remain; ICER will take time to develop approach, potentially involving pilots of dynamic pricing



Evaluating the GRACE framework

- Methods for modifying the measure of health gain (QALY or evLYG) to reflect severity are controversial and vary across academics and HTA groups
- GRACE applies measures of risk-aversion and values of health gains at different levels of severity to modify the QALY
- ICER will work with academics and HTA groups to examine strengths and limitations of GRACE, including conceptual and practical validity, potential impact on discriminatory risk, and "fairness" across patient groups



Reflections on the Value Assessment Framework

- We use the VAF as our "guidebook" for every single ICER assessment
- We want everyone to understand how we approach value assessment to enable participation at all levels
- We value your engagement and support, and we could not do this effectively without your constructive feedback

